Imcyse extends Series B financing

Country

Belgium

Imcyse SA has raised an additional €21.3 million in Series B financing in order to advance its pipeline of immunotherapy compounds and simultaneously brought Pfizer Inc on board as a shareholder. Earlier, Imcyse announced a licensing deal with Pfizer to develop a preclinical asset for rheumatoid arthritis.